These results were aligned with the findings of Lipari et al. and Jeffery et al. [12,13], indicating that elevated MMP2 levels contribute to disease progression in CRC patients and have a detrimental effect on CRC pathogenesis. This evidence concerns the gene MMP2 and colorectal carcinoma.